Medpace Holdings, Inc. MEDP
We take great care to ensure that the data presented and summarized in this overview for Medpace Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MEDP
View all-
Black Rock Inc. New York, NY2.58MShares$841 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.55MShares$830 Million0.02% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT909KShares$296 Million1.51% of portfolio
-
State Street Corp Boston, MA753KShares$246 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA628KShares$205 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA566KShares$184 Million0.04% of portfolio
-
Riverbridge Partners LLC552KShares$180 Million2.55% of portfolio
-
Td Asset Management Inc503KShares$164 Million0.16% of portfolio
-
Bessemer Group Inc Woodbridge, NJ501KShares$163 Million0.28% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny492KShares$161 Million0.26% of portfolio
Latest Institutional Activity in MEDP
Top Purchases
Top Sells
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Insider Transactions at MEDP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+1.17%
|
-
|
|
Sep 30
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71
+10.73%
|
-
|
|
Sep 30
2024
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+0.36%
|
-
|
|
Aug 23
2024
|
Robert O. Kraft Director |
SELL
Open market or private sale
|
Direct |
3,774
-87.89%
|
$1,471,860
$390.73 P/Share
|
|
Aug 23
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,774
+46.78%
|
$158,508
$42.62 P/Share
|
|
Aug 22
2024
|
Robert O. Kraft Director |
SELL
Open market or private sale
|
Direct |
4,353
-89.33%
|
$1,697,670
$390.73 P/Share
|
|
Aug 22
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,353
+47.18%
|
$182,826
$42.62 P/Share
|
|
Aug 05
2024
|
Susan E Burwig Exec. VP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+46.51%
|
$4,500,000
$90.65 P/Share
|
|
Jun 30
2024
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+1.19%
|
-
|
|
Jun 30
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72
+12.16%
|
-
|
|
Jun 30
2024
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+0.36%
|
-
|
|
Jun 05
2024
|
Susan E Burwig Exec. VP, Operations |
SELL
Open market or private sale
|
Direct |
7,681
-50.6%
|
$3,080,081
$401.2 P/Share
|
|
May 28
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
5,695
-0.86%
|
$2,249,525
$395.49 P/Share
|
|
May 24
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
3,987
-0.6%
|
$1,574,865
$395.22 P/Share
|
|
May 22
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
55
-0.01%
|
$22,000
$400.0 P/Share
|
|
May 20
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
4,020
-0.6%
|
$1,608,000
$400.19 P/Share
|
|
May 16
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
7,060
-1.05%
|
$2,845,180
$403.09 P/Share
|
|
May 15
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
32,282
-4.56%
|
$13,074,210
$405.13 P/Share
|
|
May 10
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
4,956
-0.7%
|
$1,992,312
$402.89 P/Share
|
|
May 09
2024
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
3,486
-0.49%
|
$1,394,400
$400.17 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 120K shares |
|---|
| Open market or private sale | 2.22M shares |
|---|